Shire acquires 99.21% of Movetis shares

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that its wholly owned subsidiary Shire Holdings Luxembourg S.a.r.l. acquired 99.21% of the shares of Movetis NV on October 12, 2010, following a successful tender offer launched in September 2010.

As previously announced, Shire will proceed with a squeeze-out of those shares and warrants not tendered to the offer in accordance with applicable Belgian legislation. In this regard, an additional tender offer period opened, on the same terms, on October 12, 2010 and will close on November 2, 2010 at 4 pm CET.

Shares tendered into the additional tender offer will be settled on November 8, 2010. Shares and warrants not tendered to the additional tender offer shall be deemed transferred to Shire Holdings Luxembourg S.a.r.l. by operation of law on November 8, 2010. Payment of the offer price for shares and warrants not tendered to the additional tender offer will be deposited with the Deposito-en Consignatiekas/Caisse des Depots et Consignations in Belgium.

At the close of the reopened tender offer, the shares in Movetis will be delisted from Euronext Brussels. The last trading day will therefore be November 2, 2010.

Shire's offer is EUR19 in cash for each outstanding Movetis share.

SOURCE Shire plc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.